Consequently, targeting STAT3 has emerged as a prominent strategy in cancer therapy, with researchers developing small molecules, peptides, and monoclonal antibodies designed to disrupt its activity or inhibit its interactions (Wang, Liao, et al. 2024; Mohan et al. 2022; Fan et al. 2024). This evidence concerns the gene STAT3 and cancer.